Most biopharmaceutical

Size: px
Start display at page:

Download "Most biopharmaceutical"

Transcription

1 B i op r o c e s s Technical Fed-Batch Cell Culture Process Optimization A Rationally Integrated Approach Zhou Jiang, Kurt Droms, Zhaohui Geng, Susan Casnocha, Zhihua Xiao, Steve Gorfien, and Scott J. Jacobia Most biopharmaceutical production platforms are based on fed-batch cell culture protocols, which can support high volumetric productivity while maintaining low operational complexity (1). The industry is interested in developing or refining high-titer cell culture processes to meet increasing market demands and reduce manufacturing costs (2). Although advancements in cell engineering have enabled development of highperforming recombinant cell lines (3 6), improvements in cell culture media and process parameter settings are required to realize the maximum production potentials of those cells (7 8). In a fed-batch process, a basal medium supports initial growth and production, and a feed medium prevents depletion of nutrients and sustains the production phase (9). Those media can contain different assortments of nutrients to accommodate the distinct metabolic requirements during different Pr o d u c t Fo c u s: Antibodies a n d other proteins Process Focus: Pr o d u c t i o n Wh o Sh o u l d Re a d: An a l y t i c a l a n d process development personnel Ke y w o r d s : Me d i a, supplements, CHO cells, design of experiments, titer Le v e l: Intermediate production phases. Process parameter settings including feeding strategy and control parameters define the chemical and physical environments suitable for cell growth and protein production. Optimization of a fedbatch process can be achieved by development efforts addressing one or more of three major elements: basal medium, feed medium, and process settings. Given the large sets of variables in these systems, establishing a cost- and time-efficient approach for process optimization is desired but challenging. Through a study aiming to upgrade a fed-batch process, we observed that basal and feed media have interrelated impacts on process outcomes (a pairing effect ). So we required a combined optimization of basal and feed media to fulfill our objective. Here we discuss a rationally integrated approach that best serves the practices of fed-batch cell culture process optimization. Materials and Methods Chinese Hamster Ovary Cells: We used a recombinant GS-CHO cell line (both the CHOK1SV host cell line and glutamine synthetase expression vector licensed from Lonza Biologics) expressing a monoclonal antibody as the model cell line in our study. Existing Fed-Batch Cell Culture Process: Development of the existing control fed-batch process has been detailed elsewhere (). Briefly, a chemically defined medium was chosen as the basal medium, and a chemically defined feed medium was developed through a multiround statistical design of experiment (DoE) study. The process was successfully applied to both NS and CHO cell cultures. Optimization of the Process: We conducted our optimization studies using either shake flasks (Corning) or Cellferm-Pro bioreactors (DASGIP BioTools). Cells were adapted over at least three passages into the test medium variants before evaluation in cell growth performance assays. Initial bioreactor culture volume was ml. We controlled ph at 7. ±. and dissolved oxygen (DO) at 3%. Culture conditions followed the existing control process except for our designed variables. We measured cell densities and viabilities using a Vi-Cell counter (Beckman Coulter) and measured concentrations of glucose, ammonia, and lactate with a BioProfile analyzer (Nova Biomedical). We determined monoclonal antibody titers using a POROS 2-µm protein A ID 4 BioProcess International (3) Ma r c h 212

2 Figure 1: Baseline performance of batch and fed-batch cell culture processes; both were seeded at 3 x vc/ml. The fed-batch culture was fed with a control feed at 1.6% volume per day starting from day 3, and the batch control culture was maintained without feeding. Terminal IgG titers are shown relative to the batch control condition. Viable Cell Density ( 6 cells/ml) Fed-Batch Batch Figure 3: Cell growth and IgG titers from the top media mixture and control medium; cells were seeded at 3 vc/ml and cultured in batch mode. Day 7 IgG titers are shown relative to the batch control condition. Viable Cell Density ( 6 cells/ml) Top Media Mixture Medium cartridge affinity column (Life Technologies) controlled by a Waters 269 Alliance system with 2998 photodiode array detector set at 2 nm (Waters), using a purified IgG standard to establish the standard curves in each measurement. Re s u lt s Baseline Performance of the Process: We assessed our existing control process using the model cell line to establish baseline performance. As Figure 1 shows, the fed-batch process reached a peak viable cell (vc) density of 19 6 cells/ml, and the batch process (run as a control without feeding) had a peak viable cell density of 7 6 cells/ml. The feed in this process demonstrated a high baseline performance by yielding an 8.-fold titer increase over the batch control process. The IgG titer from our fed-batch process reached the multigram per liter range, which is regarded in the industry as high for a platform process. Optimization Workflow: Figure 2 depicts our optimization workflow. This project included two major phases: Phase 1 dealt with basal medium development following a three-step DoE path, and phase 2 involved a feed DoE study followed by a combined feed and process optimization. We conducted basal medium optimization through three steps of DoE experiments. First, we used a Figure 2: Optimization work-flow chart; the project had two phases, each including multiple steps. Phase 1 focused on basal medium optimization, phase 2 on feed and process optimization. } Media Mixture DoE Two-Level Phase 1: Factorial DoE Basal Medium Optimization Central Composite DoE Two-Level Factorial Feed DoE Integrated Feed and Process Optimization } Phase 2: Feed and Process Optimization media mixture DoE study to identify a basal medium formulation as a starting point for medium optimization. Our second step was a two-level factorial DoE study testing the effects of multiple nutrient groups supplementing the basal medium. The final step was a central composite DoE to determine the optimal concentrations of functional nutrient groups identified in the previous step. The media mixture layout we designed using Design-Expert software (Stat-Ease), consisted of 1 unique mixtures of four chemically defined prototype formulations. We evaluated our media mixtures with a batch cell growth performance assay. A top media mixture was identified that outperformed the control basal medium by giving 8% higher peak cell densities and 2% higher IgG titers (Figure 3). In our two-level factorial DoE study, we selected five nutrient groups to evaluate how they affect protein titer when used as basal medium supplements at two concentrations (added or not) to the top media mixture. We designed a total of 16 basal medium variants with various combinations of those five nutrient groups and assessed them in a fedbatch cell growth performance assay using the existing control feed for all conditions. As Figure 4 (left) shows, the cell cultures exhibited a wide range of growth responses to supplementation of the nutrient groups. Multiple supplemented media supported higher peak cell densities than the control condition. However, their boosted cell growth did not translate to a gain in IgG titer; none of the medium variants improved IgG titer over the control (Figure 4, right). That was contradictory to the previous batch culture evaluation of media mixtures in which improved IgG titers were observed, suggesting that the feed may have been playing a dominant role in IgG production for this process. Furthermore, statistical analyses of the results revealed that two nutrient groups had a negative effect and one Ma r c h 212 (3) BioProcess International 41

3 Figure 4: Two-level factorial DoE experiment on cell growth and IgG titers; all conditions were seeded at 3 vc/ml and fed with the original control feed at 1.6% volume per day starting day 3; (left) cell growth curves; (right) IgG titers at harvest (shown relative to fed-batch control condition denoted by the red dotted line). Viable Cell Density ( 6 cells/ml) M1 M3 M M7 M9 M11 M13 M1 M2 M4 M6 M8 M M12 M14 M Medium Variants nutrient group had a positive effect on IgG titer (p <.). In a central composite DoE study, we regrouped select nutrient groups and tested them at five different concentrations encompassing a wider range than our two-level factorial study. We designed 1 medium variants for evaluation of three nutrient groups. All variants were tested in a fed-batch growth performance assay to which the original control feed was applied. As Figure shows, this round of optimization improved cell growth; however, that did not translate into increased IgG titer. Cell growth was largely improved through basal medium optimization. By contrast, IgG-specific productivity which characterizes average productivity per cell was drastically reduced (data not shown). So an increase in titer was not achieved. Optimally in a fed-batch cell culture process, the basal medium supports cells through their growth phase and thus plays a major role in cell growth, whereas the feed medium sustains cells through the production phase for a primary contribution of increasing IgG productivity. When basal medium optimization improved cell growth, we hypothesized that a corresponding feed optimization would be required to increase the IgG titer of our fed-batch process. Further, we hypothesized that process parameters might need to be altered to realize the full potential of our new medium and feed combination. Feed Optimization: In this project, we optimized feed by testing nutrient groups as supplements to the existing feed. We selected five nutrient groups for screening at two levels: high level (with supplements added back to the control feed) and low level (the control feed without supplementation). A total of 17 feed variants reflected different combinations of supplementing the nutrient groups. In the fed-batch cell growth performance assay, we seeded all conditions in the same basal medium (the top medium identified in phase 1), feeding each one with the designated feed variant. As Figure 6 shows, multiple test conditions outperformed the control fedbatch process with regard to IgG titer, with the top condition demonstrating a 1% increase. This improvement suggested that the fed-batch process may benefit from the pairing effect described above. The control feed was originally developed to specifically match the original basal medium, which gave a high baseline performance (11). After basal medium optimization, feed modification became necessary to better match the new basal medium for superior process Figure : Central composite DoE experiment cell growth and IgG titers; all conditions were seeded at the 3 vc/ml and fed with the original control feed at 1.6% volume per day starting day 3; (left) cell growth curves; (right) IgG titers at harvest (shown relative to fed-batch control condition denoted by the red dotted line). Viable Cell Density ( 6 cells/ml) C1 C3 C C7 C9 C11 C13 C1 C2 C4 C6 C8 C C12 C BioProcess International (3) March Medium Variants

4 outcome. We conducted statistical analyses and identified two nutrient groups with significant positive effects on IgG production (p <.). Our final study was an integrated feed and process optimization. We designed five feed variants to test different concentrations of nutrient groups identified as having a significant positive effect on protein titer in our previous experiment. Using a fed-batch growth performance assay, we tested these variants in conjunction with multiple process parameters: seeding density, feeding schedule, and temperature shift. We seeded all conditions in the same basal medium, feeding each condition with the designated variant under different process settings. As Figure 7 depicts, this round of integrated optimization further improved IgG titer, with the top condition 4% higher than the control fed-batch process. This titer improvement could be primarily linked to increased IgGspecific productivity (data not shown); the accompanying cell growth augmentation was only marginal. This study involved an integrated optimization combining both feed and process optimization in one step. Although feed development and process Figure 6: Cell growth and IgG titers in the two-level factorial feed optimization study; all conditions were seeded in the same basal medium at 3 vc/ml. Each condition was fed with the designated feed variant; (left) cell growth curves; (right) IgG titers at harvest (shown relative to fed-batch control condition denoted by the red dotted line). Viable Cell Density ( 6 cells/ml) F1 F3 F F7 F9 F11 F13 F1 F17 F2 F4 F6 F8 F F12 F14 F Feed Variants FROM SCRATCH TO BATCH GMP PRODUCTION OF BIOLOGICS CREATING TOMORROW S SOLUTIONS Just give us your protein sequence and we ll do the rest. Working closely with you, we ll put our process development skills and project management expertise at your service, providing you with a GMP batch of your product highly efficient, professionally and on time. Team up with the leading innovator in E. coli production technologies and learn about ESETEC, our unique E. coli secretion technology. Visit Wacker Biotech GmbH, Jena, Germany, Tel , info.biologics@wacker.com

5 Figure 7: Cell growth and IgG titers in the integrated feed and process optimization; all conditions were seeded in the same basal medium. Each condition was fed with designated feed variant under various process settings; (a) cell growth curves; (b) IgG titers at harvest (shown relative to fedbatch control condition denoted by the red dotted line). Viable Cell Density ( 6 cells/ml) Conditions. Fully integrated optimization is challenging because of the many experimental conditions required. optimization are usually addressed in separate studies, this integrated approach can be used to deliver superior results in a shortened period. Di s c u s s i o n Basal medium, feed medium, and process parameter settings are the three major factors for fed-batch cell culture process optimization. Performance can be improved by upgrading one or more of those three elements. In phase 1 of our study, extensive basal medium development efforts improved cell growth in a fed-batch process, but IgG titer did not increase because specific productivity decreased. Subsequent feed optimization in phase 2 promptly indentified a modified feed that better matched the new basal medium developed in phase 1 and outperformed the original fed-batch control process with regard to IgG titer by restoring specific productivity. The benefit of pairing basal and feed media supports the idea that the two Figure 8: Comparing top IgG titers achieved in each step (listed chronologically); steps 1 represent the control fed-batch process, twolevel factorial DoE, central composite DoE, two-level factorial feed DoE, and integrated feed/process development, respectively. Data are relative to the control fed-batch process (denoted by the red dotted line) Step have interrelated impacts on cell culture performance. An upgraded basal medium can induce notable changes in the growth and metabolism of cells and therefore may require an accordingly modified feed to accommodate the nutrient demands of those cells. For fedbatch process optimization, improving a single element may be insufficient to improve the overall process outcome and require development efforts on the other elements. Optimization of all three elements in our fed-batch process was necessary to realize its maximal protein production potential. As Figure 8 shows, protein titer increases were not seen in this study until basal and feed were optimized in tandem. All three elements can be optimized in different ways. The most straightforward, serial approach sequentially optimizes basal medium, feed medium, and process settings. However, that overlooks the nature of networked interactions among the three elements and thus may not guarantee an optimal outcome. An iterative optimization, in which sequential optimization of one or more elements is repeated until desired results are reached, can further propel a process toward its optimal point (4). However, that approach prolongs development timelines. As a more sophisticated strategy, a fully integrated approach with simultaneous optimization of all three elements is ideal for identifying the globally optimal condition. However, implementation of the fully integrated optimization is challenging because of the many experimental conditions required, which can be on the order of thousands and exceed current development capacity. Instead, we used a semiintegrated protocol. The basal medium and feed medium were optimized sequentially, followed by a final round of integrated optimization of feed and process settings. Our approach differs from a fully integrated optimization by involving sequential steps while taking advantage of the power of multiplexed integration. This is an example of rationally integrated optimization. Under that concept, integrated optimization can be rationally designed to meet requirements and deliver significantly improved process performance. 44 BioProcess International (3) Ma r c h 212

6 Th e Best o f Bo t h Wo r l d s Because the basal medium, feed medium, and process parameter settings have interrelated roles in a fed-batch process, optimization of all three elements may be required to maximize process outcomes. A fully integrated strategy with simultaneous optimization of all elements would allow for process optimization within a shorter timeline than a sequential approach requires. However, implementing a full integration can be challenging because of the required large set of experimental conditions. As an alternative, rationally integrated approaches can be designed and used to overcome those limitations and deliver desired results for fed-batch cell culture process development. Acknowledgments The authors thank Peggy Lio and Rickard Fike for their input as well as Jaime Goldfuss and Aaron Schrader for analytical support. References 1 Fike R. Nutrient Supplementation Strategies for Biopharmaceutical Production, Part 1: Identifying a Formulation. BioProcess Int. 7() 29: Birch JR, Racher AJ. Antibody Production. Adv. Drug Deliv. Rev. 8, 26: Wurm FM. Production of Recombinant Protein Therapeutics in Cultivated Mammalian Cells. Nat. Biotechnol. 22 (11) 24: Dinnis DM, James DC. Engineering Mammalian Cell Factories for Improved Recombinant Monoclonal Antibody Production: Lessons from Nature? Biotechnol. Bioeng. 91, 2: Barnes LM, Dickson AJ. Mammalian Cell Factories for Efficient and Stable Protein Expression. Curr. Opin. Biotechnol. 17, 26: Rita Costa A, et al. Guidelines to Cell Engineering for Monoclonal Antibody Production. Eur. J. Pharm. Biopharm. 74, 2: Gorfien S. Chapter : Cell Culture Media Development: Customization of Animal Origin-Free Components and Supplements. Cell Culture and Upstream Processing. Butler M, Ed. Garland Science Publishing: New York, NY, Oxford, UK, 27: Li F, et al. Cell Culture Processes for Monoclonal Antibody Production. MAbs 2() 2: Fike R. Nutrient Supplementation Strategies for Biopharmaceutical Production, Part 2: Feeding for Optimal Recombinant Protein Production. BioProcess Int. 7(11) 29: Ma N, et al. A Single Nutrient Feed Supports Both Chemically Defined NS and CHO Fed-Batch Processes: Improved Productivity and Lactate Metabolism. Biotechnol. Prog. 2() 29: Pacis E, et al. Systematic Approaches to Develop Chemically Defined Cell Culture Feed Media. BioPharm Int. 23(11) 2: Corresponding author Zhou Jiang is a staff scientist, Zhihua Xiao and Scott J. Jacobia are senior managers, and Steve Gorfien is senior director in bioproduction R&D at Life Technologies, 317 Staley Road, Grand Island, NY 1472; , fax ; zhou.jiang@lifetech.com; Kurt Droms and Susan Casnocha are associate research fellows, and Zhaohui Geng is senior manager of biotherapeutics R&D at Pfizer Corporation, 7 Chesterfield Parkway West, Chesterfield, MO Your partner in Hydrolysate innovation Proyield for Biopharma Cost effective productivity enhancement To order reprints of this article, contact Rhonda Brown (rhondab@ fosterprinting.com) Download a low-resolution PDF online at

High yield antibody production in a disposable WAVE Bioreactor

High yield antibody production in a disposable WAVE Bioreactor High yield antibody production in a Process intensification using perfusion culture Christian Kaisermayer 1, Jianjun Yang 2 1 GE Healthcare Europe GmbH, Vienna, Austria (Christian.Kaisermayer@ge.com),

More information

How To Develop A Cell Line

How To Develop A Cell Line Advances in The Development of Biopharmaceuticals The application of modern technologies and services to the development of Biopharmaceutical processes Dr Jonathan H Dempsey Process Science Fellow Invitrogen

More information

Exciting Trends in Bioprocessing

Exciting Trends in Bioprocessing Exciting Trends in Bioprocessing Alfred Doig and Susan Dana Jones, Ph.D. April 20, 2015 BioProcess Technology Consultants, Inc. 12 Gill Street, Suite 5450 Woburn, MA 01801 Exciting Trends in Bioprocessing

More information

Accelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development

Accelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development Pharma&Biotech Accelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development James Rance PhD Head of Development Services Singapore Lonza Biologics

More information

Improving GS-CHO Cell Line Selection: Reducing Time to Clinic

Improving GS-CHO Cell Line Selection: Reducing Time to Clinic Cell Line Development and Engineering 2-6 March 2009, Berlin Improving GS-CHO Cell Line Selection: Reducing Time to Clinic Adrian Haines, 2009 Lonza Biologics plc, Slough, UK Disclaimer Certain matters

More information

The Importance of Developing a High Yield of Product

The Importance of Developing a High Yield of Product European Antibody Congress Lyon, 3 rd November 2005 The Importance of Developing a High Yield of Product John Birch, Lonza Biologics plc Monoclonal Antibodies A Success Story Fastest growing segment of

More information

Technologies for Monoclonal Antibody Production

Technologies for Monoclonal Antibody Production Technologies for Monoclonal Antibody Production First we help you bridge the distance between upstream and downstream. Then we help you shorten it. Monoclonal antibodies for therapeutic, diagnostic and

More information

Selection of Cell Lines for Manufacturing Therapeutic Antibodies by Flow Cytometric Cell Sorting. Andrew Racher Lonza Biologics

Selection of Cell Lines for Manufacturing Therapeutic Antibodies by Flow Cytometric Cell Sorting. Andrew Racher Lonza Biologics Selection of Cell Lines for Manufacturing Therapeutic Antibodies by Flow Cytometric Cell Sorting Andrew Racher Lonza Biologics Structure of Talk 1. The Problem 2. Possible Solutions 3. Solution Chosen

More information

BioProcessing J O U R N A L. Trends and Developments in BioProcess Technology. Volume 9 Issue 1 ISSN 1538-8786

BioProcessing J O U R N A L. Trends and Developments in BioProcess Technology. Volume 9 Issue 1 ISSN 1538-8786 A Production of ISBioTech Summer 2010 Issue BioProcessing J O U R N A L Trends and Developments in BioProcess Technology Volume 9 Issue 1 ISSN 1538-8786 Trends & Developments in BioProcess Technology Novel

More information

Monoclonal antibodies

Monoclonal antibodies MAb Contaminant Removal with a Multimodal Anion Exchanger A Platform Step to Follow Protein A Kjell Eriksson, Anders Ljunglöf, Gustav Rodrigo, and Eggert Brekkan Reprinted with permission from BioProcess

More information

Application Note USD3013. Monoclonal Antibody Production in Suspension CHO Culture Using Single-Use PadReactor Mini Bioreactor

Application Note USD3013. Monoclonal Antibody Production in Suspension CHO Culture Using Single-Use PadReactor Mini Bioreactor Application Note USD313 Monoclonal Antibody Production in Suspension CHO Culture Using Single-Use PadReactor Mini Bioreactor Introduction Single use solutions are found in many applications as they offer

More information

Use of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development

Use of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development Use of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development Authors: Dr Fern Slingsby and Dr Simon Dewar Upstream Process Development FUJIFILM

More information

Application Note. Purifying common light-chain bispecific antibodies using MCSGP. Summary

Application Note. Purifying common light-chain bispecific antibodies using MCSGP. Summary Application Note Purifying common light-chain bispecific antibodies using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, biochromatography Antibodies MCSGP Bispecific antibody,

More information

Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies

Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies ISCT 2011 Annual Meeting Rotterdam, The Netherlands May 18 21, 2011 BioProcess Technology Consultants www.bptc.com

More information

QbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins

QbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins QbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins 2015. 06. 09 Green Cross Corp. Green Cross Research Center Yong Jae Kim (YJKIM@greencross.com) Biologics World

More information

ESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES. Dr Andrew Racher

ESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES. Dr Andrew Racher ESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES Dr Andrew Racher Lonza Biologics plc, 2004 Structure of talk Issues Selection of a high producing cell line Selection for process compatibility

More information

Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform

Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign

More information

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB

More information

Application Note. Separation of three monoclonal antibody variants using MCSGP. Summary

Application Note. Separation of three monoclonal antibody variants using MCSGP. Summary Application Note Separation of three monoclonal antibody variants using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, Biochromatography; FPLC Protein A-purified monoclonal

More information

Triskel: a strategic consulting firm for biopharmaceutical companies

Triskel: a strategic consulting firm for biopharmaceutical companies BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland

More information

Luca Romagnoli, Ph.D. Business Development Manager

Luca Romagnoli, Ph.D. Business Development Manager Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies

More information

Towards energy-based dynamic optimization of monoclonal antibody producing GS-NS0 Cultures

Towards energy-based dynamic optimization of monoclonal antibody producing GS-NS0 Cultures 20 th European Symposium on Computer Aided Process Engineering ESCAPE20 S. Pierucci and G. Buzzi Ferraris (Editors) 2010 Elsevier B.. All rights reserved. Towards energy-based dynamic optimization of monoclonal

More information

Mab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation.

Mab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation. Mab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation. Summary Monoclonal antibodies are expensive to develop and to manufacture.

More information

EMABling Antibody Production Platform

EMABling Antibody Production Platform EMABling Antibody Production Platform An industrial solution for the production of therapeutic antibodies with high cytotoxic activity B IOMANUFACTURING EMABling : A fully integrated development platform

More information

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB

More information

A customizable ADCC assay service for antibodies & fusion proteins.

A customizable ADCC assay service for antibodies & fusion proteins. Antibody Dependent Cell- Mediated Cytotoxicity (ADCC) Assay A customizable ADCC assay service for antibodies & fusion proteins. Our ADCC assay service accurately detects cell lysis based on LDH-release.

More information

Protein Synthesis and Purification: Microbial Versus Mammalian Systems

Protein Synthesis and Purification: Microbial Versus Mammalian Systems STREAMLINING RECOMBINANT PROTEIN PRODUCTION The pharmaceutical industry is undergoing a deep transformation from small molecule drugs to biologics. Over the last decade, the percentage share of biologic-based

More information

Quick Guide to AlphaScreen SureFire Assay Optimization

Quick Guide to AlphaScreen SureFire Assay Optimization PPLITION NOT lpha Technology Quick uide to lphascreen Sureire ssay Optimization Introduction Screening kinase activities in cell-based assays offers advantages over the more traditional biochemical approach

More information

Introduction to Bioprocessing

Introduction to Bioprocessing Introduction to Bioprocessing Cambridge Healthtech Institute Peptalk Palm Springs, CA Presented by Susan Dana Jones and Sheila Magil BioProcess Technology Consultants www.bptc.com BioProcess Technology

More information

Biotechpharma company profile

Biotechpharma company profile Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing

More information

Manufacturing processes for

Manufacturing processes for Single-Use, Continuous- Countercurrent, Multicolumn Chromatography Marc Bisschops, Lynne Frick, Scott Fulton, and Tom Ransohoff Reprinted with permission from BioProcess International 7(6) (June 2009)

More information

Integrated Protein Services

Integrated Protein Services Integrated Protein Services Custom protein expression & purification Last date of revision June 2015 Version DC04-0013 www.iba-lifesciences.com Expression strategy The first step in the recombinant protein

More information

Bioprocessing Media and Buffers Grow with Us

Bioprocessing Media and Buffers Grow with Us Bioprocessing Media and Buffers Grow with Us Experience Highly experienced media on the selection of standard media as well as development This service packaging, documentation Leading position in single-use

More information

Method Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates

Method Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates Method Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates Paula Hong and Kenneth J. Fountain Waters Corporation, 34 Maple St., Milford, MA, USA APPLICATION

More information

Next-Generation Facilities for Monoclonal Antibody Production

Next-Generation Facilities for Monoclonal Antibody Production Advancing Development & Manufacturing Facilities Next-Generation Facilities for Monoclonal Antibody Production Niels Guldager ELECTRONICALLY REPRINTED FROM JULY 2009 The biopharmaceutical industry faces

More information

Vaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010

Vaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010 Vaccine Manufacturing Facilities of the Future Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010 Challenges in the Production of Vaccines Different technology platforms make it

More information

How Profitable is Backgrounding Cattle? Dr. John Lawrence and Cody Ostendorf, Iowa State University

How Profitable is Backgrounding Cattle? Dr. John Lawrence and Cody Ostendorf, Iowa State University How Profitable is Backgrounding Cattle? Dr. John Lawrence and Cody Ostendorf, Iowa State University Many beef producers question the profitability of backgrounding cattle before selling them. Many variables

More information

In biomanufacturing based on

In biomanufacturing based on B I O P R O C E S S TECHNICAL Comparing Automated and Manual Cell Counts for Cell Culture Applications Arun Tholudur, Luis Giron, Kohinoor Alam, Tiffany Thomas, Eric Garr, Gresham Weatherly, Keith Kulowiec,

More information

Custom Antibody Services

Custom Antibody Services Custom Antibody Services Custom service offerings DNA sequence Plasmid Peptide Structure Protein Peptide Small molecule Cells Spleen Lymphocytes Antigen Preparation Immunization Fusion & Subcloning Expansion

More information

3 Chapter Three: Material and methods (clone creation, upstream and downstream process)

3 Chapter Three: Material and methods (clone creation, upstream and downstream process) 3 Chapter Three: Material and methods (clone creation, upstream and downstream process) 3.1 Model proteins and CHO cell cultures Two recombinant produced, CHO-cell-derived model-glycoproteins, a less glycosylated

More information

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project Mabsolus-2015-UK:Mise en page 1 03/07/15 14:13 Page1 Services provider Department of MABSolys from conception to validation MAB Solut is involved at each stage of your project Creation of antibodies Production

More information

BACTERIAL ENUMERATION

BACTERIAL ENUMERATION BACTERIAL ENUMERATION In the study of microbiology, there are numerous occasions when it is necessary to either estimate or determine the number of bacterial cells in a broth culture or liquid medium.

More information

Monoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.

Monoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd. Monoclonal Antibody Production: Building the Platform Andrew Clutterbuck Eden Biodesign Ltd. Questions Questions are encouraged throughout the presentation and can be asked by using the email address provided

More information

BaculoDirect Baculovirus Expression System Free your hands with the BaculoDirect Baculovirus Expression System

BaculoDirect Baculovirus Expression System Free your hands with the BaculoDirect Baculovirus Expression System BaculoDirect Baculovirus Expression System Free your hands with the BaculoDirect Baculovirus Expression System The BaculoDirect Baculovirus Expression System gives you: Unique speed and simplicity High-throughput

More information

Robert Birdsall, Eoin Cosgrave, Henry Shion, and Weibin Chen Waters Corporation, Milford, MA, USA APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS

Robert Birdsall, Eoin Cosgrave, Henry Shion, and Weibin Chen Waters Corporation, Milford, MA, USA APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS Automating the Determination of Drug-to-Antibody Ratio (DAR) of Antibody Drug Conjugates (ADCs) Based on Separation by Hydrophobic Interaction Chromatography (HIC) Robert Birdsall, Eoin Cosgrave, Henry

More information

Cell Discovery 360: Explore more possibilities.

Cell Discovery 360: Explore more possibilities. Cell Discovery 360: Explore more possibilities. Flexible solutions for the BioPharma laboratory Blood Banking Capillary Electrophoresis Centrifugation Flow Cytometry Genomics Lab Automation Lab Tools Particle

More information

Accelerating drug development to FTIH: Potential of new expression technologies

Accelerating drug development to FTIH: Potential of new expression technologies Accelerating drug development to FTIH: Potential of new expression technologies Lekan Daramola Associate Director Biopharmaceutical Development, Cell Culture & Fermentation Sciences CMC Strategy Forum

More information

One of the greatest challenges facing biopharmaceutical

One of the greatest challenges facing biopharmaceutical Monoclonal Antibody Manufacturing Strategies for the 21st Century James Blackwell, Ph.D., MBA Sr. Consultant Thomas Ransohoff, VP and Sr. Consultant Howard L. Levine, Ph.D., President and Principal Consultant

More information

Integrated Protein Services

Integrated Protein Services Integrated Protein Services Custom protein expression & purification Version DC04-0012 Expression strategy The first step in the recombinant protein generation process is to design an appropriate expression

More information

It is generally accepted that quality

It is generally accepted that quality B i op r o c e s s Technical Practical Considerations for DoE Implementation in Quality By Design Mahesh Shivhare and Graham McCreath It is generally accepted that quality cannot be tested or inspected

More information

Technology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)

Technology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com) M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over

More information

Valentina Gualato, Ph.D. Process Development Scientist

Valentina Gualato, Ph.D. Process Development Scientist COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing

More information

Host cell proteins (HCPs) are

Host cell proteins (HCPs) are B i op r o c e s s Technical Improved HCP Quantitation By Minimizing Antibody Cross- Reactivity to Target Proteins Xing Wang, Thomas Schomogy, Kristine Wells, and Ned M. Mozier Host cell proteins (HCPs)

More information

Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals

Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals Howard L. Levine and Susan Dana Jones BPI Europe 2013 Apr 17-18, 2013 Dusseldorf, Germany BioProcess Technology Consultants

More information

Process-scale purification of monoclonal antibodies polishing using Capto Q

Process-scale purification of monoclonal antibodies polishing using Capto Q GE Healthcare Life Sciences Application note 28-937-16 AB Ion exchange chromatography Process-scale purification of monoclonal antibodies polishing using Capto Q Summary Anionic exchange media are an industry

More information

Instrument services for WAVE Bioreactor systems

Instrument services for WAVE Bioreactor systems GE Healthcare Life Sciences Instrument services for WAVE Bioreactor systems Share our depth of knowledge Service designed for your peace of mind GE Healthcare Life Sciences Services has over 50 years of

More information

Transgenic technology in the production of therapeutic proteins

Transgenic technology in the production of therapeutic proteins Transgenic technology in the production of therapeutic proteins Transgenic technology represents a new generation of biopharmaceutical production system to meet the medical needs of the new millennium.

More information

THOMAS C. RANSOHOFF Vice President and Principal Consultant

THOMAS C. RANSOHOFF Vice President and Principal Consultant THOMAS C. RANSOHOFF Vice President and Principal Consultant +1.781.281.2704 (o) +1.617.759.4109 (m) transohoff@bptc.com Profile An expert in the development and scale up of biopharmaceutical processes;

More information

Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches

Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches 2008 IBC Formulation Strategies for Protein Therapeutics Tim Kelly, Ph.D.

More information

INTERFERin in vitro sirna/mirna transfection reagent PROTOCOL. 1 Standard sirna transfection of adherent cells... 2

INTERFERin in vitro sirna/mirna transfection reagent PROTOCOL. 1 Standard sirna transfection of adherent cells... 2 INTERFERin in vitro sirna/mirna transfection reagent PROTOCOL DESCRIPTION INTERFERin is a powerful sirna/mirna transfection reagent that ensures efficient gene silencing and reproducible transfection in

More information

TransIT -2020 Transfection Reagent

TransIT -2020 Transfection Reagent Quick Reference Protocol, MSDS and Certificate of Analysis available at mirusbio.com/5400 INTRODUCTION TransIT -2020 Transfection Reagent is a high-performance, animal-origin free, broad spectrum reagent

More information

Overview of Upstream and Downstream Processing of Biopharmaceuticals

Overview of Upstream and Downstream Processing of Biopharmaceuticals Overview of Upstream and Downstream Processing of Biopharmaceuticals Ian Marison Professor of Bioprocess Engineering and Head of School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland

More information

Application Note. Increasing the activity of monoclonal antibody isoforms by MCSGP. Summary

Application Note. Increasing the activity of monoclonal antibody isoforms by MCSGP. Summary Application Note Increasing the activity of monoclonal antibody isoforms by MCSGP Category Matrix Method Keywords Countercurrent chromatography, FPLC Antibodies MCSGP FPLC, Biobetters, MCSGP, countercurrent

More information

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases

More information

Advances in Biopharmaceutical and Vaccine Manufacturing Plants

Advances in Biopharmaceutical and Vaccine Manufacturing Plants Hitachi Review Vol. 62 (2013), No. 4 267 Advances in Biopharmaceutical and Vaccine Manufacturing Plants Sei Murakami, Dr. Eng. Haruo Suzuki Keisuke Shibuya, Dr. Sc. OVERVIEW: The development of innovative

More information

Notes on titering antibodies

Notes on titering antibodies Home Events This Week Bulletin Boards Lab Personnel Lab Policies Protocols MolBio Tetramers Proteins Flow Cytometry Immunoassays Instruments Computers Lab Publications Scientiific Literature Science on

More information

Multiple Products in a Monoclonal Antibody S88.01 Batch Plant

Multiple Products in a Monoclonal Antibody S88.01 Batch Plant Presented at the World Batch Forum North American Conference Chicago, IL May 16-19, 2004 900 Fox Valley Drive, Suite 204 Longwood, FL 32779-2552 +1.407.774.0207 Fax: +1.407.774.6751 E-mail: info@wbf.org

More information

Fighting the Battles: Conducting a Clinical Assay

Fighting the Battles: Conducting a Clinical Assay Fighting the Battles: Conducting a Clinical Assay 6 Vocabulary: In Vitro: studies in biology that are conducted using components of an organism that have been isolated from their usual biological surroundings

More information

Grouping to Increase Milk Yield and Decrease Feed Costs

Grouping to Increase Milk Yield and Decrease Feed Costs 61 Grouping to Increase Milk Yield and Decrease Feed Costs Michael S. Allen 1 Department of Animal Science Michigan State University Abstract There are many advantages of grouping cows to optimize their

More information

HuCAL Custom Monoclonal Antibodies

HuCAL Custom Monoclonal Antibodies HuCAL Custom Monoclonal Antibodies Highly Specific Monoclonal Antibodies in just 8 Weeks PROVEN, HIGHLY SPECIFIC, HIGH AFFINITY ANTIBODIES IN 8 WEEKS WITHOUT HuCAL PLATINUM IMMUNIZATION (Human Combinatorial

More information

"Small and large molecules bioproduction by mammalian and microbial fermentation"

Small and large molecules bioproduction by mammalian and microbial fermentation "Small and large molecules bioproduction by mammalian and microbial fermentation" H.-P. Meyer Bio/PharMOS 2004-23-25 March 2004 Symposium B Business Diversification in Life Science "Small and large molecules

More information

Advances inthe Development. of Therapeutic

Advances inthe Development. of Therapeutic Advances inthe Development of Therapeutic Monoclonal Antibodies Susan Dana Jones, Francisco J. Castillo, Howard L. Levine ABSTRACT Monoclonal antibodies (MAbs) and related products are a dominant component

More information

GenScript USA Incorporation:

GenScript USA Incorporation: New Jersey with a subsidiary site in Nanjing, China. Our dedication to innovation has led GenScript to generate a continuous flow of services and products to ease and Job ID: NJ001 Position: Head of Animal

More information

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000

More information

Potelligent CHOK1SV. European Antibody Congress 30 Nov - 02 Dec, Geneva, Switzerland. Alison Porter, 2009 Lonza Biologics plc, Slough, UK

Potelligent CHOK1SV. European Antibody Congress 30 Nov - 02 Dec, Geneva, Switzerland. Alison Porter, 2009 Lonza Biologics plc, Slough, UK Potelligent European Antibody Congress 30 Nov - 02 Dec, Geneva, Switzerland Alison Porter, 2009 Lonza Biologics plc, Slough, UK Disclaimer Certain matters discussed in this presentation may constitute

More information

Measuring Cell Viability/Cytotoxicity: Cell Counting Kit-F

Measuring Cell Viability/Cytotoxicity: Cell Counting Kit-F Introduction The Cell Counting Kit-F is a fluorometic assay for the determination of viable cell numbers. Calcein-AM in this kit passes through the cell membrane and is hydrolized by the esterase in the

More information

Biopharmaceutical Process Evaluated for Viral Clearance

Biopharmaceutical Process Evaluated for Viral Clearance Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate

More information

1.Gene Synthesis. 2.Peptide & Phospho-P. Assembly PCR. Design & Synthesis. Advantages. Specifications. Advantages

1.Gene Synthesis. 2.Peptide & Phospho-P. Assembly PCR. Design & Synthesis. Advantages. Specifications. Advantages 1.Gene Synthesis Assembly PCR Looking for a cdna for your research but could not fish out the gene through traditional cloning methods or a supplier? Abnova provides a gene synthesis service via assembly

More information

The Super-Spinner: A low cost animal cell culture bioreactor for the CO 2 incubator

The Super-Spinner: A low cost animal cell culture bioreactor for the CO 2 incubator Cytotechnology 14: 1-9, 1994. 9 Kluwer Academic Publishers. Printed in the Netherlands. The Super-Spinner: A low cost animal cell culture bioreactor for the CO 2 incubator R. Heidemann, U. Riese, D. Ltitkemeyer,

More information

Predict the Popularity of YouTube Videos Using Early View Data

Predict the Popularity of YouTube Videos Using Early View Data 000 001 002 003 004 005 006 007 008 009 010 011 012 013 014 015 016 017 018 019 020 021 022 023 024 025 026 027 028 029 030 031 032 033 034 035 036 037 038 039 040 041 042 043 044 045 046 047 048 049 050

More information

ELITE Custom Antibody Services

ELITE Custom Antibody Services ELITE Custom Antibody Services ELITE Custom Antibody Services Experience, confidence, and understanding As a manufacturer and service provider, we have the experience, confidence, and understanding to

More information

ACID-BASE TITRATIONS: DETERMINATION OF CARBONATE BY TITRATION WITH HYDROCHLORIC ACID BACKGROUND

ACID-BASE TITRATIONS: DETERMINATION OF CARBONATE BY TITRATION WITH HYDROCHLORIC ACID BACKGROUND #3. Acid - Base Titrations 27 EXPERIMENT 3. ACID-BASE TITRATIONS: DETERMINATION OF CARBONATE BY TITRATION WITH HYDROCHLORIC ACID BACKGROUND Carbonate Equilibria In this experiment a solution of hydrochloric

More information

Application Note. Determination of Nitrite and Nitrate in Fruit Juices by UV Detection. Summary. Introduction. Experimental Sample Preparation

Application Note. Determination of Nitrite and Nitrate in Fruit Juices by UV Detection. Summary. Introduction. Experimental Sample Preparation Application Note Determination of Nitrite and Nitrate in Fruit Juices by UV Detection Category Food Matrix Fruit Juice Method HPLC Keywords Ion pair chromatography, fruit juice, inorganic anions AZURA

More information

Seahorse XF Cell Mito Stress Test Kit

Seahorse XF Cell Mito Stress Test Kit Seahorse XF Cell Mito Stress Test Kit Part # 103015-100 User Guide For use with Seahorse XF e and XF Extracellular Flux Analyzers For Research Use Only 1 Table of Contents Product Description... 2 Introduction...

More information

EVALUATION OF THE EFFECT OF THE COMPOUND RIBOXYL ON THE ATP LEVEL AND CELLULAR RESPIRATION FROM HUMAN DERMAL FIBROBLASTS

EVALUATION OF THE EFFECT OF THE COMPOUND RIBOXYL ON THE ATP LEVEL AND CELLULAR RESPIRATION FROM HUMAN DERMAL FIBROBLASTS EVALUATION OF THE EFFECT OF THE COMPOUND RIBOXYL ON THE ATP LEVEL AND CELLULAR RESPIRATION FROM HUMAN DERMAL FIBROBLASTS FINAL REPORT OF THE STUDY GT050923 Study promoter: LUCAS MEYER COSMETICS ZA Les

More information

A World of Biomanufacturing: Shortages or Global Glut?

A World of Biomanufacturing: Shortages or Global Glut? A World of Biomanufacturing: Shortages or Global Glut? Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. BioProcess International Conference Vienna, Austria May 19-20, 2010 Steady growth

More information

Enzyme Kinetics: Properties of â-galactosidase

Enzyme Kinetics: Properties of â-galactosidase Enzyme Kinetics: Properties of â-galactosidase Preparation for Laboratory: Read the introduction to this laboratory before doing the Web Tutorial - Beta Galactosidase. Additional background: Freeman, skim

More information

HPLC Analysis of Acetaminophen Tablets with Waters Alliance and Agilent Supplies

HPLC Analysis of Acetaminophen Tablets with Waters Alliance and Agilent Supplies HPLC Analysis of Acetaminophen Tablets with Waters Alliance and Agilent Supplies Application Note Small Molecule Pharmaceuticals Authors Jignesh Shah, Tiantian Li, and Anil Sharma Agilent Technologies,

More information

Testing Services for Large Molecule Drug Development

Testing Services for Large Molecule Drug Development Testing Services for Large Molecule Drug Development Our mission is to extend our clients capabilities by combining scientific knowledge, capacity, regulatory expertise and flexibility to provide the trusted,

More information

KMS-Specialist & Customized Biosimilar Service

KMS-Specialist & Customized Biosimilar Service KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal

More information

Manufacturing process of biologics

Manufacturing process of biologics Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:

More information

perfectprotein Antibodies ntelechon

perfectprotein Antibodies ntelechon Antibodies ntelechon Milstein and Köhler: The hybridoma technology December 1974, Cambridge: Georges J.F. Köhler, a postdoctorial fellow of César Milstein, had given eternal life to normal antibody producing

More information

BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM

BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM FROM ORIGINATOR THROUGH COMPARABILITY TO MARKET STREAMLINE YOUR R&D, REGULATORY, ANALYTICAL, AND CLINICAL NEEDS WITH ONE PROVIDER The development pathway of

More information

Application Information Bulletin: Set-Up of the CytoFLEX Set-Up of the CytoFLEX* for Extracellular Vesicle Measurement

Application Information Bulletin: Set-Up of the CytoFLEX Set-Up of the CytoFLEX* for Extracellular Vesicle Measurement Application Information Bulletin: Set-Up of the CytoFLEX Set-Up of the CytoFLEX* for Extracellular Vesicle Measurement Andreas Spittler, MD, Associate Professor for Pathophysiology, Medical University

More information

Biopharm Roundtable. 1. What, in your opinion, is currently the single largest trend with respect to biopharmaceutical outsourcing and manufacture?

Biopharm Roundtable. 1. What, in your opinion, is currently the single largest trend with respect to biopharmaceutical outsourcing and manufacture? BIOPHARM ROUNDTABLE Biopharm Roundtable Morrey Atkinson Vice President, R&D Cook Pharmica Peter Soelkner Managing Director Vetter Pharma-Fertigung GmbH & Co. KG Johannes Reiter Cooperations Manager Sandoz

More information

Fast, easy and effective transfection reagent for mammalian cells

Fast, easy and effective transfection reagent for mammalian cells METAFECTENE EASY + Fast, easy and effective transfection reagent for mammalian cells For ordering information, MSDS, publications and application notes see www.biontex.com Description Cat. No. Size METAFECTENE

More information

Biopharmaceutical Portfolio Management Optimization under Uncertainty

Biopharmaceutical Portfolio Management Optimization under Uncertainty Ian David Lockhart Bogle and Michael Fairweather (Editors), Proceedings of the 22nd European Symposium on Computer Aided Process Engineering, 17-20 June 2012, London. 2012 Elsevier B.V. All rights reserved

More information

Transfection reagent for visualizing lipofection with DNA. For ordering information, MSDS, publications and application notes see www.biontex.

Transfection reagent for visualizing lipofection with DNA. For ordering information, MSDS, publications and application notes see www.biontex. METAFECTENE FluoR Transfection reagent for visualizing lipofection with DNA For ordering information, MSDS, publications and application notes see www.biontex.com Description Cat. No. Size METAFECTENE

More information

Choose your optimal tools for protein studies

Choose your optimal tools for protein studies Protein Purification Choose your optimal tools for protein studies Bacterial Baculoviral Cell free Mammalian Secreted Intracellular High yield Increased solubility Highest purity Highest yield His-tag

More information

Life Sciences. Antibody Screening Sandwich Assay by Label-free Epic Technology

Life Sciences. Antibody Screening Sandwich Assay by Label-free Epic Technology Life Sciences Antibody Screening Sandwich Assay by Label-free Epic Technology Jeffery J. Scibek*, Arron S. Xu*, Klaus Kaluza#, and Anthony G. Frutos* *Corning, Corning Inc, Corning, NY 14831, USA # Screening

More information